Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “IMIPRAMINE”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,171 records · Page 65Linked to original sources
PubMed1977

[Experimental investigation of psychophysiological effect of a new antidepressant (lofepramine) as compared to imipramine and placebo (author's transl)].

Using 24 non-selected healthy male students the effects of imipramine (single dose of 100 mg orally) and 4'-chloro-2-[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-propyl]-methylamino]-acetophenone-hydrochloride (lofepramine, Gamonil) (single dose of 140 mg orally) in comparison to placebo (doubleblind) on subjective, physiological and performance variables were examined. All subjects (Ss) received the three drugs in a completely counterbalanced sequence. On the basis of their scores on the Depression Scale of the Freiburger Personality Inventory (FPI, Fahrenberg) Ss were divided into two groups of 12 Ss each, "high depression" and "low depression" group. Two-way analyses of variance were computed. Imipramine and Lofepramine elevate scores in the mood scale, but only for the "high depression" group. For the Ss scoring lower in depression no such effect can be demonstrated. The physiological effects are similar. Reported side effects are less for lofepramine than for imipramine.

Antidepressive Agents↗
PubMed1979

[The open-field, non-stressed behavior of rats under the acute and chronic effect of imipramine and tranylcypromine, depending on the individual reaction type (emotional and non-emotional)].

The acute and prolonged effects of imipramine and tranylcypromine were studied on 30 emotive and 30 non-emotive mature male Wistar rats to determine whether the drugs affect the behavior of these two reaction types differently. We found that both drugs change the typical behavior of the rats in the open field, each in a different way. Acute doses of imipramine inhibit symptoms of anxiety as well as the exploratory behavior so that the rats appear totally disinterested in their environment. This finding seems to confirm the assumed central nervous suppressing effects of this drug as mentioned in the literature. Single doses of tranylcypromine have effects similar to those mentioned for imipramine; however, long-term use results in a "vitalisation" of behavior: symptoms of anxiety remain inhibited and exploratory behavior becomes dominant. Both drugs produced a certain "flattening" of behavior. Due to the effects of drugs used, the original behavioral differences without stress disappear. Prolonged use of tranylcypromine makes emotive rats totally non-emotive.

Animals↗
PubMed1983

Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

Alprazolam is the first of the triazolobenzodiazepines to be studied in a large population of depressed patients. In a six-week, double-blind multicenter comparison of alprazolam, imipramine hydrochloride, and placebo in the treatment of 723 patients with depression, the two active drugs were statistically more effective than placebo. Alprazolam was at least as effective as imipramine in relieving depressive symptoms, significantly more effective in relieving somatic symptoms, and showed an earlier onset of activity in some measurements. Anticholinergic side effects were reported most often by patients receiving imipramine, while drowsiness was the only side effect reported most often in the alprazolam group. The Feighner Diagnostic Criteria and prestudy and poststudy intercenter conferences with videotaped patient interviews ensured interrater reliability.

Adolescent↗
PubMed1980

False-negative results for urinary phenothiazines and imipramine in Forrest's qualitative assays.

When a series of patients' urine samples supplemented in vitro with chlorpromazine or imipramine was assayed with the Forrest qualitative assays, we observed an occasional false-negative result, which we found was attributable to interference by ascorbic acid. It interferes with the reagent, not with the analytes, in both assays. We easily eliminated this interference with the phenothiazine test by using an anion-exchange resin. Eliminating the interference with the assay for imipramine, however, is more difficult; false-negative results can be obtained even after ion-exchange chromatography if the imipramine concentration is less than 50 mg/L.

Ascorbic Acid↗
PubMed1983

ECG findings in geriatric depressives given trazodone, placebo, or imipramine.

ECG effects were evaluated in 60 depressed geriatric patients in a drug-free baseline state and weekly during treatment with trazodone, placebo, or imipramine. Eighteen patients underwent crossover from placebo or imipramine to trazodone. Imipramine increased heart rate and was associated with more isolated ECG complications. Trazodone and placebo did not increase heart rate and had no other significant ECG effects.

Aged↗
PubMed1984

Cardiac and antiarrhythmic effects of imipramine in patients with ventricular arrhythmias.

Imipramine is an effective antiarrhythmic agent against ventricular arrhythmias and complex features of ventricular premature depolarizations at plasma concentrations ranging from 100 to 400 ng per ml. Imipramine's effects on the electrocardiogram are similar to procaine amide and quinidine producing a slight prolongation of PR and QRS intervals. A relatively long half-life of elimination, mean = 9 + 3.7 hours, and no significant adverse effect on left ventricular function suggest imipramine will be useful even for patients with depressed cardiac function.

Anti-Arrhythmia Agents↗
PubMed1983

Anorgasmia associated with imipramine but not desipramine: case report.

A case of imipramine-induced orgasmic inhibition in a woman is reported. Desipramine, the metabolite of imipramine, did not produce this reaction. The ability of imipramine to block the CNS neuronal reuptake of serotonin (a property not shared by desipramine) is considered the probable pathophysiologic mechanism in the failure to achieve orgasm.

Desipramine↗
PubMed1984

The relationship of plasma imipramine and N-desmethylimipramine to improvement in agoraphobia.

Plasma tricyclic concentrations were assessed in 15 agoraphobic patients receiving combined imipramine and behavioral treatments. Imipramine but not N-desmethylimipramine plasma levels were found to significantly correlate with improvement. The results suggest that imipramine's effect in agoraphobia might be mediated predominantly through the serotonergic action of the parent drug. There was also suggestive evidence for differential antipanic and antiphobic-antidepressant effects. Implications for future studies of the mechanism of action of drug effects in agoraphobia are discussed.

Adult↗
PubMed1984

Imipramine inhibiton of ragweed allergic conjunctivitis.

Twenty-seven patients sensitive to ragweed pollen were treated with topical imipramine 0.05% in one eye and vehicle in the other in a double-masked fashion. The eyes treated with imipramine showed significantly less redness, tearing, and discomfort after exposure to pollen extract. Imipramine, a tricyclic antidepressant, appears to be an effective antihistamine in the eye.

Administration, Topical↗
PubMed1981

A comparison of phenelzine and imipramine in depressed inpatients.

Phenelzine and imipramine were compared double-blind, in 43 depressed inpatients. A placebo week preceded drug treatment; this allowed early identification of placebo responders who did not therefore enter the study. After three weeks treatment, the two drugs were equally effective on Hamilton, Beck and SCL-90 measures of depression and anxiety. On the the SCL-90 scales of hostility and paranoia imipramine was more effective; in some patients phenelzine was associated with increased hostility. Measurement of MAO inhibition and plasma tricyclic levels indicated that adequate doses were generally used - (mean 81 mg/day phenelzine and 144 mg/day imipramine).

Adult↗
PubMed1982

Drug-receptor interaction on plasmid elimination by phenothiazines and imipramine in Escherichia coli.

Plasmid elimination in Escherichia coli by a quaternary amine of chlorpromazine was demonstrated on different incompatibility groups of plasmid. The biological effect of the drug depends partly on the host bacteria and partly on the plasmid itself. Various receptor substrates such as adenosine, dopamine, histamine and norepinephrine do not alter the plasmid elimination by promethazine and imipramine. None of the known drug-receptors studied are involved in drug binding of the bacteria. The direct membrane action of imipramine and promethazine was demonstrated in electron microscopic studies and alterations in the bacterial membrane such as discontinuities, phase separation or rarely extensive lytic alterations were observed. Magnesium ions prevent the ultrastructural membrane alterations caused by imipramine and promethazine. There is some evidence that the drugs bind to two different receptor sites simultaneously on the plasmid replication site. The first and strongest binding has to be ionic through the side chain amino group, displacing the bivalent cations. In turn, the two aromatic rings of the fixed (ionically bound) drug molecules bind weakly through pi-electrons, hydrophobically or by a charge transfer complex. This weaker binding together with the ionic one are essential for biologic action and lead to the inhibition of plasmid replication. A schematic model of the effect of tricyclic psychotropic drugs on the bacterial membrane is proposed.

Binding Sites↗
PubMed1982

Toxic hepatitis and single daily dosage imipramine therapy.

Liver function abnormalities have occasionally been associated with imipramine since the drug was introduced in 1957. The mechanism by which the drug produces hepatotoxicity has not been determined but may involve a direct toxic effect or a hypersensitivity reaction. In this case, a patient receiving 6 mg/kg (300 mg) of imipramine daily developed elevated liver enzymes while the plasma imipramine concentration was found to be in a therapeutic range. This case suggests that single daily dosing of tricyclic antidepressants may be more hazardous to the liver than divided doses.

Adult↗
PubMed1982

[3H-Imipramine binding to human platelets. A peripheral index in depressive syndromes (author's transl)].

3H-imipramine shows specific, high-affinity binding to human platelet sites. The characteristics of these specific binding sites are very similar to those previously described in the rat brain. The inhibitory effects of 11 tricyclic antidepressants on 3H-imipramine binding to human platelets were investigated. There was a significant correlation between the inhibition observed and the average therapeutic doses of antidepressants, which suggests that the binding sites may be involved in the mode of action of these drugs. The number of binding sites (Bmax) for 3H-imipramine was compared in 39 controls and in 37 hospital patients with untreated severe depressive syndrome and was found to be significantly smaller in depressed patients, without any modification of the affinity constant Kd. The significance of these findings and their changes under treatment are discussed.

Adult↗
PubMed1978

Doxepin versus imipramine in psychoneurotic depressed patients with sleep disturbance: a double-blind study.

This double-blind randomized study compared the effects of imipramine (48 patients) and doxepin (49 patients) in psychoneurotic depressed patients with sleep disturbance symptoms. Mean doses of 112.7 mg/day for doxepin and 116.7 mg/day for imipramine were administered for a mean period of 26 days. While both drugs proved effective, 24 of 27 analyses of covariance showed imipramine to be superior to doxepin. This superiority was statistically significant for the anxiety/depression factor measured on the Hamilton Depression Scale and for the total score, general neurotic feelings factor, cognitive performance difficulty factor and anger-hostility cluster on the Lepman-Rickels Scale. Mild-to-moderate side effects were prevalent to a comparable degree in both treatment groups.

Adjustment Disorders↗
PubMed1981

The effects of imipramine on socio-emotional and alimentary motivated behavior in dogs.

The effects of imipramine on spontaneous locomotor activity, alimentary motivated behavior and socio-emotional behavior were investigated in five dogs. In all dogs the main imipramine-bound effect was the decrease of locomotor activity in the open field. In four behaviorally normal dogs, performance of other tests was only slightly affected by imipramine treatment. An improvement in performance of various tasks and socio-emotional reactions was observed only in one neurotic dog.

Animals↗
PubMed1980

Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study.

Sixty unipolar depressed geriatric outpatients were subjects in a double-blind study of a new antidepressant, trazodone, versus imipramine and placebo. Over the four week study, patients in the two active medication groups improved significantly compared to placebo on both observer and self-ratings. Although imipramine and trazodone had similar therapeutic efficacy, trazodone was judged to have fewer side effects than imipramine, suggesting that trazodone may have particular clinical utility in the geriatric population which is especially vulnerable to cardiovascular and anticholinergic side effects.

Aged↗
PubMed1995

A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.

The aim of this study is to compare the antidepressant efficacy and side effects of moclobemide with imipramine (a standard antidepressant). Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) with selectivity for the MAO type A isoenzyme. Thirty-two patients who met DSM-3R criteria for major depressive episode or dysthymia were randomly assigned to receive either moclobemide or imipramine in a double-blind prospective study. The results indicated no difference in antidepressive efficacy between the two drugs, but imipramine had more anticholinergic side-effects. Neither drug had significant effects on pulse rate, blood pressure, weight changes or blood chemistry. These results were confirmed by previous studies.

Adult↗
PubMed1994

[Effects of repeated treatment with electroconvulsive shock or imipramine on [3H]prazosin binding sites in the rat frontal cortex].

Two subtypes (alpha 1A and alpha 1B) of alpha 1-adrenoceptors have been defined on the basis of radioligand binding studies with 2-(2,6-dimethoxyphenoxyethyl)-1,4-benzodioxane (WB4101). In contrast, functional studies with blood vessels have proposed another subclassification, where the alpha 1-adrenoceptors can be classified into putative two (alpha 1H and alpha 1L) or three (alpha 1H, alpha 1L and alpha 1N) subtypes. The present study was performed to elucidate the effects of repeated treatment with electroconvulsive shock (ECS) or imipramine on the subtypes of alpha 1-adrenoceptors. The density of the alpha 1H binding sites (including alpha 1A and alpha 1B binding sites) in the frontal cortex was increased by repeated treatment with ECS but decreased by imipramine. These treatments did not change the density of alpha 1L binding sites. These results indicated that repeated treatment with ECS and imipramine had different effects on the alpha 1H binding sites in the rat frontal cortex. In addition, the effects of antipsychotic drugs, antidepressant drugs and calcium channel antagonists on [3H]prazosin binding were studied. The order of inhibition of [3H]prazosin binding was: antipsychotic drugs (1.4-4.2 nM) > antidepressant drugs (69-116 nM) > calcium channel antagonists. The calcium channel antagonists, verapamil (720 nM), diltiazem (4.3 microM) and nicardipine (75 microM) were weakly bound. These results suggested that the antimanic effects of calcium channel antagonists were not associated with inhibition of alpha 1-adrenoceptors.

Animals↗